Myrna Candelaria

3.3k total citations
88 papers, 2.5k citations indexed

About

Myrna Candelaria is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Myrna Candelaria has authored 88 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 22 papers in Oncology and 17 papers in Hematology. Recurrent topics in Myrna Candelaria's work include Epigenetics and DNA Methylation (16 papers), Lymphoma Diagnosis and Treatment (14 papers) and Histone Deacetylase Inhibitors Research (13 papers). Myrna Candelaria is often cited by papers focused on Epigenetics and DNA Methylation (16 papers), Lymphoma Diagnosis and Treatment (14 papers) and Histone Deacetylase Inhibitors Research (13 papers). Myrna Candelaria collaborates with scholars based in Mexico, United States and Colombia. Myrna Candelaria's co-authors include Alfonso Dueñas‐González, Lucely Cetina, Enrique Pérez‐Cárdenas, Lucía Taja‐Chayeb, Carlos Pérez‐Plasencia, Aurora González‐Fierro, Erick de la Cruz‐Hernandez, Claudia Arce, Catalina Trejo‐Becerril and Luis A. Herrera and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Myrna Candelaria

83 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Myrna Candelaria Mexico 25 1.4k 563 336 299 272 88 2.5k
Christoph Mundhenke Germany 28 703 0.5× 906 1.6× 280 0.8× 206 0.7× 403 1.5× 106 2.3k
Yasunobu Kanamori Japan 26 1.0k 0.7× 1.1k 1.9× 328 1.0× 245 0.8× 186 0.7× 72 2.5k
Anneke Geurts‐Moespot Netherlands 30 804 0.6× 524 0.9× 127 0.4× 193 0.6× 233 0.9× 75 2.9k
Sarah P. Blagden United Kingdom 34 1.8k 1.3× 1.1k 2.0× 234 0.7× 151 0.5× 366 1.3× 154 3.2k
Carolyn Y. Muller United States 35 1.2k 0.8× 972 1.7× 592 1.8× 498 1.7× 378 1.4× 104 3.4k
Ivo Meinhold‐Heerlein Germany 27 800 0.6× 528 0.9× 343 1.0× 87 0.3× 247 0.9× 133 2.5k
Pascal Bonnier France 31 895 0.6× 1.4k 2.6× 262 0.8× 265 0.9× 235 0.9× 90 2.7k
Andrew R. Clamp United Kingdom 24 734 0.5× 739 1.3× 222 0.7× 67 0.2× 276 1.0× 116 2.0k
Roshan Agarwal United Kingdom 30 1.7k 1.2× 1.1k 2.0× 452 1.3× 118 0.4× 479 1.8× 61 3.8k
Fabian Trillsch Germany 25 802 0.6× 577 1.0× 389 1.2× 209 0.7× 187 0.7× 128 2.1k

Countries citing papers authored by Myrna Candelaria

Since Specialization
Citations

This map shows the geographic impact of Myrna Candelaria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Myrna Candelaria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Myrna Candelaria more than expected).

Fields of papers citing papers by Myrna Candelaria

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Myrna Candelaria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Myrna Candelaria. The network helps show where Myrna Candelaria may publish in the future.

Co-authorship network of co-authors of Myrna Candelaria

This figure shows the co-authorship network connecting the top 25 collaborators of Myrna Candelaria. A scholar is included among the top collaborators of Myrna Candelaria based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Myrna Candelaria. Myrna Candelaria is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Candelaria, Myrna, et al.. (2024). Characterizing the Mutational Landscape of Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Mexican Patients. International Journal of Molecular Sciences. 25(17). 9328–9328. 2 indexed citations
2.
3.
Candelaria, Myrna & Alfonso Dueñas‐González. (2021). Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. Therapeutic Advances in Hematology. 12. 155281355–155281355. 16 indexed citations
4.
Avilés‐Salas, Alejandro, et al.. (2021). Primary myocardial diffuse large B cell lymphoma. Report of one case. Revista médica de Chile. 149(8). 1231–1235. 2 indexed citations
5.
Gutiérrez, Olga, et al.. (2020). Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case. Revista médica de Chile. 148(9). 1357–1361. 1 indexed citations
6.
Candelaria, Myrna, Derlis Gonzalez, Márcia Torresan Delamain, et al.. (2019). Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. Leukemia & lymphoma. 60(14). 3375–3385. 24 indexed citations
7.
Candelaria, Myrna, et al.. (2017). Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS). Annals of Hematology. 96(11). 1825–1832. 14 indexed citations
8.
Reynoso‐Noverón, Nancy, et al.. (2016). Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico. BioMed Research International. 2016. 1–10. 8 indexed citations
9.
10.
Candelaria, Myrna, Aurora González‐Fierro, Catalina Trejo‐Becerril, et al.. (2010). Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Annals of Hematology. 90(4). 379–387. 57 indexed citations
11.
Candelaria, Myrna, et al.. (2009). Pharmacogenetics and pharmacoepigenetics of gemcitabine. Medical Oncology. 27(4). 1133–1143. 22 indexed citations
12.
13.
Wegman-Ostrosky, Talía, Myrna Candelaria, & Alfonso Dueñas‐González. (2007). Epigenetic and Hematological Malignancies. 2 indexed citations
14.
Cetina, Lucely, et al.. (2007). The prognostic significance of leukocytosis in cervical cancer. International Journal of Gynecological Cancer. 17(2). 465–470. 25 indexed citations
15.
Candelaria, Myrna, et al.. (2006). Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiation Oncology. 1(1). 15–15. 82 indexed citations
16.
Serrano‐Olvera, Alberto, Alfonso Dueñas‐González, Dolores Gallardo‐Rincón, Myrna Candelaria, & Horacio Astudillo‐de la Vega. (2006). Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treatment Reviews. 32(3). 180–190. 120 indexed citations
17.
Candelaria, Myrna, et al.. (2005). Neoplasia gestional trofoblástica. Experiencia del INCan. Gaceta Mexicana de Oncología. 4(6). 147–151.
18.
Chávez‐Blanco, Alma, Víctor M. Pérez-Sánchez, Aurora González‐Fierro, et al.. (2004). HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer. 4(1). 59–59. 58 indexed citations
19.
Candelaria, Myrna, et al.. (2002). Gastrointestinal Pneumatosis After Docetaxel Chemotherapy. Journal of Clinical Gastroenterology. 34(4). 444–445. 25 indexed citations
20.
Colman, M., et al.. (1988). A Comparison of the Radiation Sensitivities of Non-tumorigenic and Tumorigenic Human Hybrid Cell Lines. International Journal of Radiation Biology. 53(4). 609–616. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christoph Mundhenke Breakdown of academic impact, for papers by Yasunobu Kanamori Breakdown of academic impact, for papers by Anneke Geurts‐Moespot Breakdown of academic impact, for papers by Sarah P. Blagden Breakdown of academic impact, for papers by Carolyn Y. Muller Breakdown of academic impact, for papers by Ivo Meinhold‐Heerlein Breakdown of academic impact, for papers by Pascal Bonnier Breakdown of academic impact, for papers by Andrew R. Clamp Breakdown of academic impact, for papers by Roshan Agarwal Breakdown of academic impact, for papers by Fabian Trillsch
Rankless by CCL
2026